Company profile: Lava Therapeutics
1.1 - Company Overview
Company description
- Provider of a bispecific antibody platform engaging gamma-delta (Vγ9Vδ2) T cells for treatment of hematological and solid cancers. Offers the Gammabody® platform to generate T cell engagers targeting tumor-associated antigens, and drug candidates LAVA-051 for hematologic malignancies and solid tumors, and LAVA-1207 for metastatic castration-resistant prostate cancer.
Products and services
- LAVA-051: Drug candidate from the Gammabody platform that engages Vγ9Vδ2 T cells to treat hematological malignancies and solid tumors, Vγ9Vδ2-engaging
- LAVA-1207: Gammabody platform candidate aimed at treating metastatic castration-resistant prostate cancer by engaging Vγ9Vδ2 T cells to attack tumors, Vγ9Vδ2-targeted
- Gammabody® Platform: Generates bispecific engagers targeting Vγ9Vδ2 T cells and tumor-associated antigens for hematological and solid cancer treatment, and develops potent, safe, cost-effective biopharmaceuticals, next-generation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lava Therapeutics
Theriva Biologics
HQ: United States
Website
- Description: Provider of biologics for the prevention and treatment of serious infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theriva Biologics company profile →
Immunomedics
HQ: United States
Website
- Description: Provider of monoclonal antibody-based products for the treatment of cancer and other serious diseases, specializing in their development as part of a corporate objective to become a fully-integrated biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunomedics company profile →
Theraclion
HQ: France
Website
- Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclion company profile →
EMcision
HQ: United Kingdom
Website
- Description: Provider of medical devices for gastrointestinal applications, offering the Habib EndoHPB, an endoscopic bipolar RF probe developed to ablate tissue in the gastro-intestinal tract, and the Habib Endoblate, a bipolar RF probe for endoluminal ablation of gastrointestinal tumours.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMcision company profile →
Cellinfinity Bio
HQ: United States
Website
- Description: Provider of a machine-learning-driven genome editing platform and engineered cell therapies. Offers CLASH to enable precise, replicable site-specific edits across up to 20,000 genes to discover enhancements for cell therapy; HYPERBOOSTS (gain-of-function) and ENDOMODS (loss-of-function) genes; OPTI-CARS CAR design optimizations; and Supercharged Cell Therapy CAR-T and CAR-NK cells enhanced for potency, persistence, penetration, and memory against solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellinfinity Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lava Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lava Therapeutics
2.2 - Growth funds investing in similar companies to Lava Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lava Therapeutics
4.2 - Public trading comparable groups for Lava Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →